Feed aggregator

October concession increase for Risperidone 2mg tablets

PSNC News - 16 November 2018 - 3:00pm

Following further representations from PSNC, there will be an increase to the October 2018 price concession for Risperidone 2mg tablets.

The price concession is now set at £20.00 for a pack of 60 tablets. This revised price will be automatically applied to any prescriptions for Risperidone 2mg tablets submitted in October prescription bundles.

Originally imposed at a price of £1.80 by the Department of Health and Social Care (DHSC), PSNC requested a review of the concessionary price on behalf of community pharmacy contractors.

This concession has been put in place for October 2018 only and announcements about any November concessions will be made in due course.

Please do continue to report supply issues using PSNC’s generic shortages form which can be found here.

 

Categories: National News

Drug Tariff Watch: December 2018 changes

PSNC News - 16 November 2018 - 9:00am

The Preface lists additions, deletions and alterations to the Drug Tariff. Below is a quick summary of the changes due to take place from 1st December 2018.

Part VIIIA additions

Category A

  • Tenofovir 245mg tablets (30)

Category C:

  • Co-trimoxazole 80mg/400mg/5ml solution for infusion ampoules (10) – Aspen Pharma Trading Ltd
  • Dexamethasone 8mg tablets (30) – Teva UK Ltd
  • Dexibuprofen 300mg tablets (60) – Seractil
  • Fondaparinux sodium 1.5mg/0.3ml solution for injection pre-filled syringes (10) – Arixtra
  • Fondaparinux sodium 10mg/0.8ml solution for injection prefilled syringes (10) – Arixtra
  • Fondaparinux sodium 2.5mg/0.5ml solution for injection pre-filled syringes (10) – Arixtra
  • Fondaparinux sodium 5mg/0.4ml solution for injection prefilled syringes (10) – Arixtra
  • Fondaparinux sodium 7.5mg/0.6ml solution for injection pre-filled syringes (10) – Arixtra
  • Gentamicin 20mg/2ml solution for injection ampoules (5) – Wockhardt UK Ltd
  • Gentamicin 5mg/1ml solution for injection ampoules (5) – Gentamicin Intrathecal
  • Glycopyrronium bromide powder for solution for iontophoresis (3g) – AMCo
  • Heparin sodium 5,000units/1ml solution for injection ampoules (10) – Wockhardt UK Ltd
  • Lidocaine 200mg/20ml (1%) solution for injection vials (10) – Hameln Pharmaceuticals Ltd
  • Lidocaine 400mg/20ml (2%) solution for injection vials (10) – Hameln Pharmaceuticals Ltd
  • Liquid paraffin liquid (150ml) – Bell,Sons & Co (Druggists) Ltd
  • Liquid paraffin liquid (2000ml) – J M Loveridge Ltd
  • Liquid paraffin liquid (5000ml) – J M Loveridge Ltd
  • Metronidazole 500mg/100ml infusion 100ml bags (20) – AAH Pharmaceuticals Ltd
  • Morphine sulfate 5mg/5ml solution for injection ampoules (10) – Torbay Pharmaceuticals
  • Octreotide 1mg/5ml solution for injection vials n (1) – Pfizer Ltd
  • Octreotide 50micrograms/1ml solution for injection ampoules (5) – Sandostatin
  • Paracetamol 1g/100ml solution for infusion vials (10) – Accord Healthcare Ltd
  • Phenobarbital 60mg/1ml solution for injection ampoules (10) – Martindale Pharmaceuticals Ltd
  • Sodium bicarbonate 8.4% (1mmol/ml) solution for injection 250ml bottles (10) – AAH Pharmaceuticals Ltd
  • Sodium chloride 30% solution for infusion 100ml vials (10) – Torbay Pharmaceuticals
  • Sodium chloride 30% solution for infusion 50ml vials (10) – Torbay Pharmaceuticals
  • Sodium valproate 300mg/3ml solution for injection ampoules (5) – Episenta
  • Sodium valproate 400mg/4ml solution for injection ampoules (5) – Wockhardt UK Ltd
  • Tenofovir 123mg tablets (30) – Viread
  • Tenofovir 163mg tablets (30) – Viread
  • Tenofovir 204mg tablets (30) – Viread
  • Tobramycin 240mg/6ml solution for injection vials n (1) – Pfizer Ltd
  • Tobramycin 80mg/2ml solution for injection vials n (1) – Nebcin
  • Tobramycin 80mg/2ml solution for injection vials (5) – Pfizer Ltd
  • Tranexamic acid 500mg/5ml solution for injection ampoules (10) – Cyklokapron
  • Triamcinolone hexacetonide 20mg/1ml suspension for injection ampoules (10) – Intrapharm Laboratories Ltd
  • Vancomycin 1g powder for solution for infusion vials (10) – Flynn Pharma Ltd
  • Vancomycin 500mg powder for solution for infusion vials (10) – Flynn Pharma Ltd

Part VIIIA amendments

  • Chloramphenicol 5% ear drops n (10ml) – Martindale Pharmaceuticals Ltd is changing to Category A
  • Clonazepam 500micrograms/5ml oral solution sugar free (150ml) – Rosemont Pharmaceuticals Ltd is changing to Category A
  • Diclofenac sodium 100mg modified-release tablets (28) – Volsaid Retard 100 is changing to Fenactol Retard
  • Diclofenac sodium 75mg modified-release tablets (56) – Volsaid Retard 75 is changing to Fenactol SR
  • Morphine sulfate 10mg/1ml solution for injection ampoules (10) – Wockhardt UK Ltd is changing to Category A
  • Ranitidine 150mg/5ml oral solution sugar free (150ml) – Creo Pharma Ltd is changing to Category A
  • Tobramycin 300mg/5ml nebuliser liquid ampoules (56(4 x n14)) – Tobi is changing to Tymbrineb
  • Ursodeoxycholic acid 300mg tablets (60) – Wockhardt UK Ltd is changing to Category A

Part VIIIA deletions

  • Inositol nicotinate 500mg tablets (100) – Hexopal
  • Inositol nicotinate 750mg tablets (112) – Hexopal Forte

Part IX deletions

It is important to take careful note of removals from Part IX because if you dispense a deleted product, prescriptions will be returned as disallowed.

Product Size, type, product code Snap dressing kit – Gauze All sizes Reusable Pens – AllStar All types and sizes Vacuum Pumps – Owen Mumford Ltd – Rapport Premier SM2200 Leg Bags – L.In.C Medical Systems – LINC-Flo sterile leg bag with lever tap, adjustable inlet tube 350ml bag (LM350AD-L) Belts – AMI Medical Ltd – Suportx Ostomy/Hernia Support Belt All except 15cm depth Colostomy bags – ConvaTec Ltd – Colodress Plus (Stomahesive Wafer) Closed Pouches Opaque and clear starter holes Colostomy bags – ConvaTec Ltd – Esteem Closed Pouches with Integral filter All types and sizes Colostomy bags – ConvaTec Ltd – Esteem+ Closed Pouches with Integral filter X Small – opaque All sizes Ileostomy bags – ConvaTec Ltd – Esteem One-Piece Convex Drainable Pouch with InvisiClose Outlet All types and sizes Pressure plates/shields – Salts Healthcare – Convex Plate for Light White Bag All sizes Pressure plates/shields – Salts Healthcare – Plastic Retaining Shield Single 833008 Two piece ostomy systems – ConvaTec Ltd – Esteem Synergy ileostomy bag S1007F, S1021F, S1212F, S1221F, S1222F and S1231F Two piece ostomy systems – Oakmed Ltd – Option Connect 2 colostomy bag with filter, Clear JH520 Two piece ostomy systems – Oakmed Ltd – Option Connect 2 ileostomy bag with filter, Clear JH220 and JH120

Want to learn more about recent Dispensing & Supply news? Read our monthly updates here.

Categories: National News

Quality Payments: NSAID audit now available

PSNC News - 16 November 2018 - 8:30am

Specialist Pharmacy Service has published the non-steroidal anti-inflammatory drug (NSAID) audit, which community pharmacy contractors will need to complete if they intend to claim for the NSAID quality criterion at the February review point of the Quality Payments Scheme.

Contractors will need to have completed the audit, have notified a patient’s GP where professional concerns are identified, share their anonymised data with NHS England (by submitting this to the NHS Business Services Authority (NHS BSA) who are collecting this information on behalf of NHS England) and have incorporated the learning of the audit into future practice by the review point (15th February 2019) to meet the NSAID quality criterion.

Data must be collected for two weeks with a minimum of ten patients participating in the audit. All patients aged 65 years or over who collect a prescription for any oral NSAID or cyclo-oxygenase-2 (COX2) selective inhibitor (this does not include patients prescribed aspirin) should be included in the audit. In cases where there is difficulty in finding ten patients to participate, the audit should be extended to four weeks after which contractors can submit the data with the number of patients they have if less than ten.

Contractors can choose to enter the data directly onto a web-based platform or use the paper form (a standalone form is available at psnc.org.uk/qpaudit) to collect the data and then transfer the data onto a web-based platform to submit their results to NHS BSA. Two web-based systems are available for the audit; PharmOutcomes* or the NHS BSA Snap Survey.

Having reviewed both systems, PharmOutcomes has the following advantages over the NHS BSA Snap Survey:

  • PharmOutcomes can send an automatic referral letter to a patient’s GP practice (if the NHS BSA Snap Survey is used, contractors will need to manually send this referral letter (a template letter is available at psnc.org.uk/qpaudit);
  • A permanent patient record will be stored on PharmOutcomes; and
  • Contractors will not be required to submit their data once they have entered all their audit data onto PharmOutcomes, the system will automatically do this for contractors (if using the NHS BSA Snap Survey, contractors will need to remember to press the ‘Submit’ button once they have completed all their data entry for this to be submitted to NHS BSA. Failure to submit the data will mean the contractor does not meet the NSAID quality criterion).

*The NSAID audit on PharmOutcomes is freely available to all contractors; PSNC has agreed to use their licence to provide access.

FAQs

Q. When do I need to complete the audit?
Contractors can pick a two-week period between November 2018 and 15th February 2019 to complete the audit; however, contractors are encouraged to not leave completion of the audit until February 2019 in case the data collection period needs to be extended to four weeks if contractors have difficulty in finding ten patients to participate.

Q. Will both of the web-based systems calculate my audit results?
Yes. Both of the web-based systems will calculate a contractor’s results. If PharmOutcomes is used, contractors will be able to access the results in the ‘Reports’ section and can print this off as evidence of meeting the NSAID quality criterion. If the NHS BSA Snap Survey is used and the contractor enters an email address when submitting their results, the contractor will be emailed the results of their audit; this email should be retained as evidence of having met the NSAID quality criterion.

Contractors will, however, need to record how they have incorporated the learning of the audit into future practice elsewhere, as this information cannot be recorded on either of the web-based platforms.

Q. If I have not used PharmOutcomes before, how do I obtain log in details?
If a contractor has not used PharmOutcomes before, log in details can be obtained by sending a message to the PharmOutcomes helpdesk. Contractors will need to provide details of the pharmacy, contact information and an email address to issue the login details to.

Q. Where do I access the NSAID audit on PharmOutcomes?
When you log into PharmOutcomes select ‘Services’; you should see ‘NSAID GI Safety Audit 2018/19’ under the ‘National Audits’ heading.

If you have mislaid your PharmOutcomes login details, visit the Help page.

Categories: National News

Workforce concerns raised in advance of NHS long-term plan

PSNC News - 15 November 2018 - 2:54pm

A report on the NHS workforce published today warns that staff shortages could triple in a decade.

Analysis by the Health Foundation, the King’s Fund and the Nuffield Trust – presented in The health care workforce in England: Make or break? – suggests that the health service could be short of more than 350,000 staff by 2030.

The NHS is struggling to recruit and retain the staff needed to meet rising demand and, if this continues at the same rate, the report argues that it could lead to growing waiting lists and a deterioration in the quality of care provided.

The think tanks propose five key tests, which they say the NHS long-term plan will need to pass:

  1. address workforce shortages in the short term;
  2. address workforce shortages in the long term;
  3. support new ways of working;
  4. address race and gender inequalities in pay and progression; and
  5. strengthen workforce and service planning at all levels of the system.

Under test 3, the report advises that existing healthcare staff should be “contributing at the optimum level of their skill set”, suggesting that “pharmacists can take on medication reviews and some elements of long-term condition management”.

Alastair Buxton, PSNC Director of NHS Services, said:

“We agree that HM Government and NHS leaders need to address the mounting challenges facing the NHS workforce, however the network of over 11,600 community pharmacies are ideally placed to assist. As pressure on the NHS workforce increases, it is more important than ever that we make best use of community pharmacies. There is much more that they could do to help keep people healthy and out of hospitals, in particular by caring for people with long-term conditions, being the first port of call for healthcare advice and acting as health and wellbeing hubs.”

Categories: National News

MHRA Drug Safety Update – November 2018

PSNC News - 14 November 2018 - 2:46pm

Date issued: 14th November 2018

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 12 Issue 4, November 2018) has been published and includes articles on:

  • Hydrochlorthiazide: risk of non-melanoma skin cancer, particularly in long-term use.
  • Systemic and inhaled fluoroquinolones: small increased risk of aortic aneurysm and dissection; advice for prescribing in high risk patients.
  • Support Yellow Card: help improve the safety of medicines in pregnancy and breastfeeding, and in babies and children.

To sdee the latest MHRA Drug Safety Update in full, visit the GOV.uk website.

 

Categories: National News

CPPE Corner: Mary Seacole Leadership Programme for community pharmacy

PSNC News - 14 November 2018 - 2:42pm

Community pharmacists and pharmacy technicians can develop their leadership and management skills with an interactive programme from the Centre for Pharmacy Postgraduate Education (CPPE). We spoke to Lesley Grimes, CPPE lead pharmacist, learning development, to find out more.

Following the success of the first cohorts of the Mary Seacole Leadership Programme for community pharmacy in 2017, we have collaborated with the NHS Leadership Academy to offer the Mary Seacole Leadership programme to pharmacists and pharmacy technicians working in community pharmacy.

Places on the programme are fully funded by the Pharmacy Integration Fund (PhIF). To apply, you need to register for an account with the NHS Leadership Academy and then complete the online registration form.

While some of the cohorts have already been filled, there are still plenty of spaces available in a number of cohorts across the country including:

  • Reading
  • London
  • Liverpool
  • Wimborne (Dorset)
  • Coventry
  • Leeds
  • Nottingham

We have also recently opened up a new cohort in Birmingham that will start on 13th March 2019. The next two cohorts are in Liverpool and Wimborne (Dorset) and the deadlines for applications are on 27th November 2018 and 29th November 2018 respectively.

The Mary Seacole Leadership programme is designed to help you feel more confident in your leadership skills by helping you to identify your strengths and areas for improvement and finding the right style to suit you. The programme is comprised of a six-month interactive online course with support from an online tutor and three compulsory one-day workshops.

On the dedicated Mary Seacole page on the CPPE website, you can find a collection of quotes and video testimonials from participants of the programme, who share their thoughts and experiences.

Categories: National News

Medical device alert and recall – potential breach in sterile barrier packaging of some products manufactured by ConvaTec Limited

PSNC News - 14 November 2018 - 12:40pm

ConvaTec has voluntarily initiated a recall of specific product codes of Suction Catheters, Gastroenteral Tubes, Intermittent Urology Catheters and sterile Urine Drainage Bags due to the potential breach in sterile barrier packaging. Only the identified product codes and affected lots within this notice may have a potential breach in the sterile barrier packaging.

Action
  • Refer to the manufacturer’s Field Safety Notice FSN for a list of affected product codes and affected lots.
  • Stop using and quarantine affected devices as directed in the manufacturer’s FSN.
  • Complete the ‘Recall Response Form for END USERS’ in the FSN and return to convatecproductrecall@stericycle.com to arrange return of affected device(s).
  • Report any incidents or complaints involving this product to unomedical-uk.customerservice@convatec.com.

 

Date issued: 14th November 2018

MDA number: MDA/2018/034

Affected products: Full list

Manufacturer contacts

ConvaTec Limited Tel: 01244 832206

Recall centre:  convatecproductrecall@stericycle.com

Email: unomedical-uk.customerservice@convatec.com

 

To view the alert please visit the GOV.UK website.

Categories: National News

Christmas opening hours

PSNC News - 13 November 2018 - 5:08pm

Community pharmacy contractors do not have to open on days which are specifically mentioned in the Regulations (namely Christmas Day, Good Friday and Easter Sunday) or a day which has been specifically designated as a ‘bank holiday’, unless directed to open by their local NHS England team.

In December, contractors in England will not be required to open on the following days (unless otherwise directed by their local NHS England team):

  • Christmas Day (25th December 2018)
  • Boxing Day (26th December 2018)

Contractors will also not be required to open on New Year’s Day which falls on Tuesday 1st January 2019.

PSNC’s annual opening hours factsheet provides contractors with a quick reference guide on which public and bank holidays pharmacies can close without giving notice. This is available to download here.

Categories: National News

Mitomycin-C 10mg Powder for Solution for Injection (Kyowa): Company led drug alert

PSNC News - 12 November 2018 - 4:17pm

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company led drug recall, to be actioned, for certain batches of: Mitomycin-C Kyowa 10mg Powder for Solution for Injection.

Date issued: 12th November 2018

CLDA number: (18) A/09

MDR number: MDR 06-11/18

Batch number: 6058517

The above batch is being recalled because an out of specification result for sub visible particles was recorded at the 39 month time point.

Company contact for stock enquiries:

Martin Smith

Tel: 01896 664030

Email: Martin.Smith@kyowakirin.com

Company contact for medical information enquiries:

Gary Speake

Tel: 01896 664029

Email: Medicalaffairs@kyowakirin.com or Gary.speake@kyowakirin.com

 

To view the alert please visit the GOV.UK website.

 

 

Categories: National News

FMD webinar now on-demand

PSNC News - 8 November 2018 - 1:15pm

Community pharmacy contractors can now access an online recording of PSNC’s recent webinar about the Falsified Medicines Directive (FMD).

More than 1,000 people registered for yesterday’s webinar hosted by Alastair Buxton, PSNC’s Director of NHS Services. Alastair used the event to explain how the introduction of FMD will affect the day-to-day working of community pharmacy teams and what they need to do to prepare.

Some of the feedback we have received so far:

“I enjoyed the FMD Webinar. The length of time allocated was just right.” – Pharmacist

“Excellent way of passing the news and educating pharmacists in the UK, thank you very much for your hard work.” – Pharmacy Manager

“Very well presented. Thank you.” – Director/Owner

During the webinar, Alastair described the new processes that FMD will introduce and outlined the guidance and resources developed by the UK FMD Working Group for Community Pharmacy. He also answered a number of viewers’ questions.

With the implementation of FMD now less than three months away (February 2019), this webinar provides contractors and their teams with key actions for them to undertake in advance of that date.

Click here to view an on-demand version of the webinar.*

You can also click here to view the slide pack used in the webinar.

*Please note, to watch the recording, you will need to register (or input the email address you registered with previously).

Categories: National News

PSNC October Meeting: summary for contractors now available

PSNC News - 7 November 2018 - 5:07pm

PSNC’s October meeting was held on the 9th and 10th of the month in Swindon, and key agenda items included:

Download the summary of the October PSNC meeting here.

Further details regarding PSNC’s ongoing work will be shared on the website as soon as possible.

Categories: National News

Secretary of State advances the prevention agenda

PSNC News - 6 November 2018 - 5:50pm

The Secretary of State for Health and Social Care, Matt Hancock MP, has released a policy paper setting out the Government’s plan to put prevention at the centre of healthcare.

The paper, Prevention is better than cure, sets out plans to diagnose cancer earlier, tackle obesity and use technology to predict illness, in a drive to increase life expectancy by five years. It also stresses that individuals need to take extra responsibility for their wellbeing by adopting healthier lifestyles.

Mr Hancock announced that a Green Paper on Prevention will be published in the first half of 2019. This sits alongside his Department’s wider work in creating a long-term plan for the NHS.

PSNC’s response to the long-term plan consultation called for further commissioning of services to enable community pharmacies to do more to help people to stay healthy and so we welcome a reference to this in the policy paper:

‘The Government wants to encourage more people to make the most of their local pharmacy, and for local pharmacies to play a stronger role in helping people stay healthy.  There are almost 10,000 community pharmacies registered as Healthy Living Pharmacies in England. They deliver a wide range of lifestyle and health interventions, and promote wellbeing and self-care services.’

After Mr Hancock outlined his plans during a session at the House of Commons, Bim Afolami, MP for Hitchin and Harpenden, asked what his views are for community pharmacy as part of the strategy for prevention and Mr Hancock replied that community pharmacies have a “hugely important role to play in keeping people out of hospital and in supporting GP surgeries by doing more”.

Pauline Latham, MP for Mid Derbyshire, followed this up with a suggestion that the Secretary of State visit a community pharmacy in her constituency and Mr Hancock indicated that he would do so as part of a nearby visit due to take place later this month.

PSNC Chief Executive Simon Dukes said:

“We agree with the Secretary of State that we must do more to support preventative healthcare – this should help both people to live longer, healthier lives, and the health service to manage the increasing demands being placed on it. We were pleased to note the acknowledgement in this policy paper that local pharmacies can play a stronger role in helping people to stay well. We very much agree – community pharmacies are ideally placed to help people to stay healthy and avoid visits to hospital – and look forward to working with HM Government to make this shared vision a reality.”

Categories: National News

Update to adrenaline 150 microgram auto-injector validation protocol – urgent action required by pharmacy teams

PSNC News - 6 November 2018 - 3:41pm

A revised interim protocol on dispensing adrenaline 150 microgram auto-injectors has been issued by the Department of  Health and Social Care (DHSC).

Stock levels are now sufficient to ensure that – with immediate effect – every patient that presents a prescription will be able to have access to at least two adrenaline auto-injectors that are either in date or have a formally extended expiry date

Supplies may be constrained until the end of the year due to the backlog of patients requiring new devices.

The existing dispenser and wholesaler prescription validation processes will continue for all adrenaline 150 microgram auto-injector prescriptions (private and NHS).

Steps for pharmacies to take:

1. Read the updated protocol from DHSC, noting in particular:

  • The revised flow chart of questions to ask patients to ascertain those who are in most need of supply;
  • The extension to the usability of some batches of Jext 150 and 300 micrograms, previously advised of EpiPen 300 microgram expiry extension; and

2. Read the updated FAQs prepared by DHSC

3. Implement the protocol with immediate effect

Note this advice is interim and will be reviewed and relaxed whenever possible, but remains in force until further notice.

Please see our dedicated adrenaline resource page for all the latest and previous guidance following the adrenaline 150 microgram auto-injector supply disruption.

 

Categories: National News

Change in the classification of certain glucosamine containing products

PSNC News - 6 November 2018 - 12:37pm

Glucosamine containing products (GCPs), marketed as food supplements, with dosage levels of base glucosamine at 1178mg/day or higher can no longer be sold or supplied by pharmacy teams as they are now considered unauthorised medicines. It is important to note that under Regulation 47 of the Human Medicines Regulations 2012 it is an offence to sell or supply an unauthorised medicinal product (unless an exception applies). GCPs with a daily dose of base glucosamine at, or exceeding 1178mg/day are now regarded as medicines. In practice, this mainly affects food supplements which are marketed with daily dosage levels of 1500mg glucosamine sulphate or glucosamine hydrochloride1. GCPs that already have a valid marketing authorisation (for example, Dolenio) remain unaffected.

The reclassification follows a 2016 Court of Appeal Judgement, after which the Medicines and Healthcare products Regulatory Agency (MHRA) conducted a review to understand how and why glucosamine is used by consumers. The review found that GCPs are mainly used for medicinal purposes to treat symptoms of osteoarthritis of the knee and for general joint health. The evidence of pharmacological effect was then used to determine the dosage levels of base glucosamine (1178mg/day) at which GCPs cannot be sold without a valid marketing authorisation.

Information for Pharmacy Teams

MHRA have advised that affected GCPs should be removed from counter and dispensary shelves to avoid the inadvertent sale or supply of unauthorised medicinal products. Any prescriptions received for GCPs with a daily dose of base glucosamine at 1178mg which cannot be met by a licenced product should be referred back to the prescriber.

GCPs that can no longer be dispensed or sold over-the-counter as food supplements:

  • GCPs with a daily dose of base glucosamine at 1178mg/day or higher

GCPs that can legally be dispensed or sold over-the-counter as food supplements:

  • GCPs with a daily dose of base glucosamine less than 1178mg

 

If you require further information on this change, please contact borderline_medicine@mhra.gov.uk

For the MHRA news story go to the MHRA website here

 

1 1500mg glucosamine sulphate or glucosamine hydrochloride contain base glucosamine levels of 1178mg and 1246mg respectively.

Glucosamine sulphate is available in two salt forms; a sodium chloride and potassium chloride salt form. This means that, in practice, more than 1500mg of either salt form is added to achieve 1500mg of glucosamine sulphate and, therefore, a base glucosamine level of 1178mg.

In licensed medicines 1884.60mg of the sodium salt is added to achieve 1500mg/day of glucosamine sulphate, providing 1178mg of base glucosamine.

Glucosamine sulphate [2NaCl] contains 79.6% glucosamine sulphate and 62.5% base glucosamine.
Glucosamine sulphate [2KCl] contains 75.4% glucosamine sulphate and 59.2% base glucosamine.

 

Categories: National News

Quality Payments: DoS Profile Updater now available

PSNC News - 5 November 2018 - 3:53pm

The Directory of Services (DoS) Profile Updater, which community pharmacy contractors will need to use to meet the DoS quality criterion of the second Quality Payments Scheme 2018/19, is now available.

Contractors who plan to claim for the DoS quality criterion at the February 2019 review point are required to edit or confirm the information about their pharmacy is correct on the DoS Profile Updater between 10am on 5th November and 11:59pm on 15th February 2019 to meet the DoS quality criterion. This process is the same for ‘bricks and mortar’ pharmacies and distance selling pharmacies.

Contractors are reminded that they are required to ensure their NHS 111 DoS entry is up-to-date, which includes bank holiday opening hours. The bank holiday opening hours that contractors need to add to meet the DoS quality criterion are as follows:

Friday 19th April 2019 Good Friday Sunday 21st April 2019 Easter Sunday* Monday 22nd April 2019 Easter Monday Monday 6th May 2019 Early May bank holiday Monday 27th May 2019 Spring bank holiday

Guidance on how to edit or confirm the information about a pharmacy is correct is available on the DoS Profile Updater website (this can also be accessed by clicking on ‘Help’ at the bottom of the screen on the DoS profile updater homepage). Contractors are strongly advised to read the guidance to ensure they fully understand how to meet the quality criterion.

Once the details on the DoS Profile Updater have been edited or confirmed and then submitted, the contractor will receive an email to confirm this. This email should be retained as evidence of meeting the DoS quality criterion.

Further information on the DoS quality criterion is available on psnc.org.uk/QPDoS

*Although Easter Sunday is not officially a bank holiday, NHS England has requested that contractors add their opening hours for this date to assist local NHS England teams and DoS leads so they know which pharmacies will be open over the Easter weekend.

Frequently asked questions

Q. I updated my pharmacy’s details on the DoS Profile Updater in October 2018, therefore do I meet the quality criterion?
No. To meet the DoS quality criterion, contractors must check the pharmacy details and submit this information on the DoS Profile Updater between 10am on 5th November 2018 and 11.59pm on 15th February 2019.

Q. There are other bank holiday dates listed (before Easter and after the Spring bank holiday), do I need to add my opening hours for these bank holidays?
No. To meet the DoS quality criterion, contractors must add their opening hours for the bank holidays listed above. Completion of the other bank holidays is not mandatory to meet the quality criterion but if contractors know this information and wish to add it then they may do so.

Q. What do I do if I don’t receive an email confirming that I have submitted information on the DoS Profile Updater?
The email should be received instantaneously after submitting the information on the DoS Profile Updater; however, please allow up to two hours for the email to be delivered. To help ensure contractors receive their confirmation emails, contractors are advised to add noreply@dos-profile.service.nhs.uk to their safe senders list before they update their profile. Alternatively, contractors will need to check their junk email folder in case the email has been inappropriately filed. If the emails are not received, please email exeter.helpdesk@nhs.net to confirm that the submission has been received.

Q. What do I do if I am experiencing technical difficulties accessing the DoS Profile Updater?
If contractors have any technical difficulties accessing the DoS Profile Updater, they can email the NHS Digital helpdesk (exeter.helpdesk@nhs.net) or call them on 0300 303 4034.

Categories: National News

Identifying carers and care workers eligible for a flu vaccination

PSNC News - 2 November 2018 - 11:17am

Carers and employed care workers who are aged 18 years or over are included in the group of patients eligible for an NHS flu vaccination under the national Flu Vaccination service.

It is really important for carers and care workers to get vaccinated as if they were to catch flu and become ill, the welfare of the people they care for could be at risk. By being vaccinated, they will also be less likely to pass on the flu virus to the people they care for, which could have serious consequences for their health.

Unpaid carers

It can be difficult to identify who is a carer. A carer is a person who provides unpaid care for a family member, partner or friend who cannot cope without their support due to an illness, frailty, disability, a mental health problem or an addiction. The term ‘carer’ is sometimes confused with a care worker or care assistant; however, the difference is that a carer is unpaid whereas a care worker or care assistant is paid for looking after someone.

In the 2017/18 flu season only 39.9% of England’s carers were vaccinated against flu, which was slightly lower compared to 2016/17.

Community pharmacy contractors are therefore encouraged to try to maximise the number of carers and care workers that they vaccinate. To help with this, there are resources available on the PSNC website, which were created by PSNC and Carers Trust, to assist pharmacy teams in identifying carers who may be eligible for a flu vaccination:

  • flu vaccination poster – this poster is specifically aimed at carers; and
  • the 60-second pharmacy flu chat – this suggests how you can engage someone you think might be a carer in a quick conversation about why they should consider getting vaccinated.

PSNC has also produced a small double-sided carer flu flyer which can be attached to patients’ medicines bags highlighting that carers are eligible for a flu vaccination and states three reasons why they should have a flu vaccination.

In addition, Carers Trust has worked with NHS Employers to produce a document which contains a script and FAQs to help healthcare professionals have conversations with carers about the flu vaccination.

All of these documents can be accessed on the Identifying carers eligible for a flu vaccination page.

Carers Trust has also produced ‘ten signs that tell community pharmacy teams that someone may be a carer’. These are listed in the box below:

Social care (employed care or domiciliary care worker) and hospice workers

Health and social care staff, employed by a registered residential care/nursing home or registered domiciliary care provider or a voluntary managed hospice provider, who are directly involved in the care of vulnerable patients/clients are eligible for a free NHS flu vaccination.

To assist pharmacy teams, PSNC has produced the following resources:

  • template letter to local care providers – this can be used to inform them that community pharmacy teams can vaccinate social care workers;
  • template evidence of employment letter – pharmacy teams can share this template with employers of social care workers to use as proof of eligibility for vaccination; and
  • poster and counter top notice – this is aimed at social care workers to inform them they are eligible for a free NHS flu vaccination at the pharmacy.

These resources are available on the Flu Vaccination – promoting the service to patients page.

Further information on the Flu Vaccination Service can be found on psnc.org.uk/flu

Categories: National News

October 2018 Price Concessions/NCSO – FINAL update

PSNC News - 1 November 2018 - 4:00pm

Department of Health and Social Care (DHSC) has today (01/11/2018) set the FINAL price concessions for October 2018.

The new additions to the October 2018 price concessions list are below:

Drug Pack Size Price Concession Allopurinol 100mg tablets 28 £2.54 Allopurinol 300mg tablets 28 £5.83 Furosemide 40mg tablets 28 £2.49 Lamotrigine 100mg tablets 56 £20.76 Lamotrigine 200mg tablets 56 £24.17 Lamotrigine 50mg tablets 56 £8.95 Lercanidipine 10mg tablets 28 £4.02 Lercanidipine 20mg tablets 28 £7.87 Losartan 50mg tablets 28 £1.40 Naproxen 250mg tablets 28 £2.30 Nebivolol 5mg tablets 28 £6.54 Ondansetron 4mg tablets 10 £16.59 Ramipril 2.5mg tablets 28 £3.93 Risperidone 1mg tablets 20 £4.80 Risperidone 2mg tablets 60 £1.80 Risperidone 3mg tablets 60 £37.02 Risperidone 4mg tablets 60 £25.70 Risperidone 500microgram tablets 20 £3.03 Sevelamer 800mg tablets 180 £60.02 Telmisartan 40mg tablets 28 £9.31

DHSC previously (26.10.2018) granted the following list of price concessions:

Drug Pack Size Price Concession Brimonidine 0.2% eye drops 5ml £3.17 Diamorphine 10mg powder for solution for injection ampoules 5 £15.47 Hydroxocobalamin 1mg/1ml solution for injection ampoules 5 £9.50 Latanoprost 50micrograms/ml eye drops 2.5ml £9.50 Levetiracetam 100mg/ml oral solution sugar free 300ml £27.30 Metronidazole 400mg tablets 21 £7.00 Naproxen 500mg tablets 28 £5.00 Nicorandil 10mg tablets 60 £3.39 Propranolol 10mg tablets 28 £3.07 Propranolol 40mg tablets 28 £2.72 Propranolol 80mg tablets 56 £5.00 Ramipril 10mg tablets 28 £5.00 Tadalafil 5mg tablets 28 £28.50 Topiramate 50mg tablets 60 £9.38 Valsartan 40mg capsules 28 £5.15

DHSC previously (23.10.2018) granted the following price concessions

Drug Pack size Price Concession Amisulpride 100mg tablets 60 £8.25 Amisulpride 200mg tablets 60 £13.40 Amisulpride 50mg tablets 60 £5.22 Buprenorphine 2mg sublingual tablets sugar free 7 £5.25 Buprenorphine 8mg sublingual tablets sugar free 7 £15.40 Orlistat 120mg capsules 84 £24.01 Ramipril 5mg tablets 28 £5.54 Topiramate 100mg tablets 60 £18.68 Valsartan 160mg capsules 28 £11.95 Valsartan 80mg capsules 28 £9.95

No additional endorsements are required for price concessions. A price concession only applies for the month in which it is granted.

If you have problems obtaining a Part VIII product or problems obtaining the product at the stated Drug Tariff price, please report the issue to PSNC using the online feedback form on the PSNC Website.
Please include full details of the supplier and price paid for any products sourced above the Drug Tariff price. PSNC will investigate the extent of the problem and if appropriate discuss the issue with DHSC.

Categories: National News

FMD: 100 days to go – sign up for our webinar

PSNC News - 1 November 2018 - 1:46pm

Community pharmacy contractors need to comply with the requirements of the Falsified Medicines Directive (FMD) in one hundred days’ time (9th February 2019).

To mark this key date on the road to FMD implementation, PSNC has undertaken a full review of the content of the FMD Source website, with updated information, resources and new FAQs being added.

Pharmacy contractors that have not yet put in place plans to comply with the FMD requirements are advised to visit the How to get going with FMD page on the FMD Source website, for guidance from the UK  FMD Working Group for Community Pharmacy.

FMD webinar

PSNC will be holding a webinar on FMD on Wednesday 7th November at 7.00pm.

On the night Alastair Buxton, PSNC’s Director of NHS Services, will explain how the introduction of FMD will affect the day-to-day working of community pharmacy teams and what they need to do to prepare.

As well as describing the new processes that FMD will introduce, Alastair will also outline the guidance and resources developed by the UK FMD Working Group for Community Pharmacy, plus where to find further information and support. During the 60-minute webinar there will also be an opportunity for viewers to ask questions.

With the implementation of FMD just three months away, this webinar will provide contractors and their teams with key actions for them to undertake in advance of that date.

Register for our FMD webinar here

 

Categories: National News

MPs hear best practice in community pharmacy policy from the devolved nations

PSNC News - 1 November 2018 - 12:38pm

The All-Party Pharmacy Group (APPG) met yesterday (31st October) to hear about how community pharmacy is developing in Scotland, Wales and Northern Ireland and what learnings England could take from this.

The meeting was chaired by Sir Kevin Barron MP and attended by Steve Double MP (APPG Vice-Chair) and Alex Chalk MP (Parliamentary Private Secretary to Matt Hancock, the Secretary of State for Health and Social Care).

Discussion was focused around the strategies and objectives for community pharmacy in the devolved nations, plus examples of best practice from the different regions. The witnesses included: Harry McQuillan, Chief Executive of Community Pharmacy Scotland; Gerard Greene, Chief Executive of Community Pharmacy Northern Ireland; and Russell Goodway, Chief Executive of Community Pharmacy Wales. Simon Dukes, PSNC Chief Executive, was also in attendance as an observer.

Steve Double MP asked the negotiators what they thought the key challenges for community pharmacy were and all three representatives addressed a desire to move away from a contract modelled on dispensing. The group also heard about the challenge of moving services from pilot phases to national commissioning and why better IT integration is needed for pharmacy.

Sir Kevin Barron MP asked how pharmacies could help patients with minor ailments and long-term conditions, and the witnesses shared examples of services in their nations that were successful. MPs heard about the Common Ailments Service in Wales, where patients can access pharmacy treatment and advice for 26 conditions and Scotland’s Chronic Medication Service, a service for patients with long-term conditions, which was estimated to have dispensed 134,000 items last month.

Alex Chalk MP asked the witnesses what key message they would convey to the Secretary of State for Health and Social Care about community pharmacy. Harry McQuillan stated that community pharmacy is a ‘willing partner’ and cited key areas of pharmacy integration with GP practices in Scotland as an example of how the professions can work together to produce good outcomes. Gerard Greene felt there needed to be a change in the direction of travel. He argued that primary care goes beyond general practice and highlighted how the accessibility of community pharmacies makes them ideally placed to support other primary care colleagues. Russell Goodway thought that there was not enough clarity between the Government and the community pharmacy sector, and called for a stronger, clearer vision as to where the sector might be in five years’ time.

The APPG is now working on a report based on the findings of this recent session, looking into how community pharmacy in England might be able to learn from examples within the devolved nations. Details of the report will be available on the PSNC website once it has been published.

Categories: National News

Funding 2018/19 webinar now on-demand

PSNC News - 31 October 2018 - 1:00pm

Community pharmacy contractors can now access an online recording of PSNC’s recent webinar on the 2018/19 funding settlement.

Almost 500 people registered for yesterday’s webinar hosted by PSNC Chief Executive Simon Dukes and Director of Pharmacy Funding Mike Dent. Simon and Mike used the webinar to answer contractors’ questions about the settlement, outlining what it means for your pharmacy and for the sector more broadly.

During the webinar, the presenters outlined the 2018/19 community pharmacy funding settlement and the background to its agreement, as well as explaining the changes to the Single Activity Fee and Category M prices. They described the differences that contractors will see in their payments from the NHS and explained to listeners where to find resources to help estimate the potential changes to your income.

This webinar was organised at short notice because PSNC is keen to share as much information about the funding settlement as we can and to answer any questions from contractors. If you weren’t able to join us, hopefully this recording of both the presentation and Q&A session will address some of your queries.

Click here to view an on-demand version of the webinar.*

You can also click here to view the slide pack used in the webinar.

*Please note, to watch the recording, you will need to register (or input the email address you registered with previously).

Some of the feedback we have received so far:

“Having heard your webinar congrats on your openness and transparency.”
Superintendent Pharmacist

“I think it was a great idea to reach out to contractors in this way. A perfect opportunity for timely two way communication.” – LPC Chief Officer

“Very clear and reasonable explanations. I’m pleased that such impressive characters are looking after the interests of community pharmacy.” – National Pharmacy Adviser

Categories: National News
Syndicate content